MedTrace Logo

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

NCT05438888 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77814

Last updated 2024-05-20

Study results available
· View outcomes & findings →

Summary

The objective of this study is to investigate safety and effectiveness of apixaban compared to warfarin in very elderly patients with Non-valvular atrial fibrillation (NVAF). In addition to the absolute age, effects on higher age-related risk factors on relative risk of apixaban to warfarin is also investigated through subgroup analyses.

Conditions

  • Non-valvular Atrial Fibrillation

Interventions

DRUG

Warfarin

This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.

DRUG

Apixaban

This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2022-10-19
Completion
2022-10-19

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05438888 on ClinicalTrials.gov